Related Experiment Video
Updated: Apr 10, 2026
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
54.2K
Plying potency assays for immunotherapy of solid tumors.
Jorge S Burns1, Riana Gjeta2, Petr Lesný3
1Department of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Italy.
Frontiers in Immunology
|April 9, 2026
Summary
Developing robust potency assays for solid tumor immunotherapies is crucial. New strategies integrate advanced models and analytics to ensure effective cellular therapies, like CAR T cells, for better patient outcomes.
Area of Science:
- Immunology
- Biotechnology
- Oncology
Background:
- Current cellular immunotherapy potency assays are insufficient for solid tumors.
- Solid tumors present unique challenges including trafficking, persistence, and microenvironment.
Purpose of the Study:
- To propose advanced strategies for cellular immunotherapy potency assays.
- To address the limitations of current assays in the context of solid tumors.
Main Methods:
- Utilizing critical quality attributes and mechanism of action for assay design.
- Exploring 3D models, spatial biology, real-time technologies, and AI analytics.
- Developing a "plying" framework for layered potency assessment.
Main Results:
- The proposed strategies integrate microenvironmental factors and single-cell dynamics.
- A "plying" framework offers a structured approach from release testing to exploratory profiling.
- This facilitates clinically relevant and regulatorily acceptable potency assurance.
Conclusions:
- Advanced potency assays are essential for solid tumor immunotherapies.
- Integrating novel technologies and a structured framework improves assay relevance and reliability.
- This work provides a path towards more effective cellular therapies for solid tumors.
